Natco Pharma net profit down 23.44 percent at Rs 517.9 crore in Q2

Written By :  Ruchika Sharma
Published On 2025-11-15 09:57 GMT   |   Update On 2025-11-15 09:57 GMT

New Delhi: Natco Pharma has announced a 23.44 percent drop in its consolidated net profit for the second quarter ending September 30, 2025. The company reported a consolidated net profit of Rs 517.9 crore, compared to Rs 676.5 crore in the same period of the previous fiscal year.

The decline was attributed to higher research and development (R&D) expenses and a one-time employee bonus.

Consolidated revenue from operations in the second quarter stood at Rs 1,363 crore, as against Rs 1,371.1 crore in the corresponding period last fiscal, it added.

Advertisement
Total expenses in the quarter under review stood at Rs 849.3 crore, as compared to Rs 616.7 crore in the same period a year ago, PTI reported.
During the quarter, the company incurred substantial R&D expenses on bioequivalence and one-time employee bonuses, in addition to other business-related provisions, Natco Pharma said.
Formulations export revenue was lower at Rs 1,147 crore in the second quarter, compared to Rs 1,211.3 crore in the year-ago period. The active pharmaceutical ingredients (API) vertical recorded Rs 53.9 crore, as against Rs 49.6 crore, it added.
The company declared a second interim dividend of Rs 1.50 per equity share of Rs 2 each for the financial year 2025-26.

Read also: Natco Pharma acquires 35.75% stake in Adcock Ingram for USD 226 million

NATCO Pharma Limited is a public limited company, listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of c. US$ 2 billion. Established in 1981, NATCO Pharma has evolved into a diversified pharmaceutical manufacturer, with a primary focus on research and development, manufacturing, and global marketing of both finished dosage formulations and active pharmaceutical ingredients. NATCO Pharma operates across various geographies (in over 50 countries), including emerging and developed markets, with a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories.

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News